Each NULIPID-10 film-coated tablet contains Atorvastatin calcium trihydrate equivalent to Atorvastatin 10 mg
Each NULIPID-20 film-coated tablet contains Atorvastatin calcium trihydrate equivalent to Atorvastatin 20 mg
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, which is an enzyme that converts 3-hydroxy-3-methylglutaryl-coenzym A to mevalonate, a precursor of sterols including cholesterol in patients with a history of homozygous and heterozygous hypercholesterolemia (FH), non-history of hypercholesterolemia and mixed dyslipidemia, Atorvastatin lowers total-C (total cholesterol), LDL-C (low density lipoprotein cholesterol) and apo B (apolipoprotein B). Atorvastatin also lowers VLDC- (very low density lipoprotein cholesterol) and TG (triglycerides) and produces a variable increase in HDL-C (high density lipoprotein cholesterol).
Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to increase LDL uptake and catabolism.
Atorvastatin reduces LDL production and LDL particle count. Atorvastatin resulted in a large and sustained increase in LDL receptor activity coupled with beneficial changes in the quality of circulating LDL particles. Atorvastatin is effective in lowering LDL in patients with a history of homozygous hypercholesterolemia, a population that usually does not respond to fat-lowering drugs.
- Atorvastatin is indicated as adjunctive therapy to diet to reduce total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides in patients with primary hypercholesterolemia, complex hypercholesterolemia and a history of heterozygous or homozygous hypercholesterolemia when the response to diet or non-pharmacological measures is inadequate.
- Prevention of cardiovascular complications
- As adjunctive therapy to diet to reduce total-C, LDL-C and apo-B levels in postmenarchal boys and girls. 10 – 17 years, with a family history of heterozygous hypercholesterolemia if after adequate diet therapy still has: LDL remains ≥ 190 mm/dl and there is a family history of premature heart disease or ≥ 2 other cardiovascular disease risk factors (CVD) found in pediatric patients child.
A common starting dose is 10 mg once daily. Dosage range is 10 – 80 mg once a day. Doses may be given at any time of day, with or without food. Initial and maintenance doses should be appropriate to the individual’s baseline LDL-C level, the goals of therapy and the patient’s response. After initiation and/or at the time of titration of Atorvastatin, lipid levels are analyzed within 2 to 4 weeks and dose adjustment is required.
Presentation and Registration Number:
- NULIPID®-10 Film Coated Tablets Box, 3 strips @ 10 film coated tablets No. Reg. :DKL1808025817A1
- NULIPID®-20 Film Coated Tablets Box, 3 strips @ 10 film coated tablets No. Reg. :DKL1808025817B1
ON MEDICAL PRESCRIPTION ONLY
This post was written by admin